vs
Side-by-side financial comparison of Community Healthcare Trust Inc (CHCT) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Community Healthcare Trust Inc is the larger business by last-quarter revenue ($31.5M vs $18.6M, roughly 1.7× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 8.1%, a 57.7% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 4.8%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 7.0%).
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
CHCT vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $31.5M | $18.6M |
| Net Profit | $2.5M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | — | 56.3% |
| Net Margin | 8.1% | 65.7% |
| Revenue YoY | 4.8% | 1808.5% |
| Net Profit YoY | 60.2% | 376.5% |
| EPS (diluted) | — | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $31.5M | — | ||
| Q4 25 | $30.9M | $18.6M | ||
| Q3 25 | $31.1M | $334.0K | ||
| Q2 25 | $29.1M | $1.4M | ||
| Q1 25 | $30.1M | $257.0K | ||
| Q4 24 | $29.3M | $977.0K | ||
| Q3 24 | $29.6M | $660.0K | ||
| Q2 24 | $27.5M | $736.0K |
| Q1 26 | $2.5M | — | ||
| Q4 25 | $14.4M | $12.3M | ||
| Q3 25 | $1.6M | $-8.6M | ||
| Q2 25 | $-12.6M | $-6.9M | ||
| Q1 25 | $1.6M | $-5.4M | ||
| Q4 24 | $1.8M | — | ||
| Q3 24 | $1.7M | $-2.8M | ||
| Q2 24 | $-10.4M | $-14.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.3% | ||
| Q3 25 | — | -2516.5% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -3350.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1563.6% | ||
| Q2 24 | — | -1255.0% |
| Q1 26 | 8.1% | — | ||
| Q4 25 | 46.6% | 65.7% | ||
| Q3 25 | 5.3% | -2572.2% | ||
| Q2 25 | -43.2% | -504.8% | ||
| Q1 25 | 5.3% | -2097.7% | ||
| Q4 24 | 6.3% | — | ||
| Q3 24 | 5.9% | -425.5% | ||
| Q2 24 | -37.9% | -1964.4% |
| Q1 26 | — | — | ||
| Q4 25 | $0.52 | $0.25 | ||
| Q3 25 | $0.03 | $-0.17 | ||
| Q2 25 | $-0.50 | $-0.14 | ||
| Q1 25 | $0.03 | $-0.11 | ||
| Q4 24 | $0.04 | — | ||
| Q3 24 | $0.04 | $-0.06 | ||
| Q2 24 | $-0.42 | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.6M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $421.3M | $49.4M |
| Total Assets | $1.0B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.6M | — | ||
| Q4 25 | $3.3M | $40.0M | ||
| Q3 25 | $3.4M | $37.9M | ||
| Q2 25 | $4.9M | $44.8M | ||
| Q1 25 | $2.3M | $40.6M | ||
| Q4 24 | $4.4M | $59.3M | ||
| Q3 24 | $2.8M | $68.8M | ||
| Q2 24 | $734.0K | $73.0M |
| Q1 26 | — | — | ||
| Q4 25 | $532.2M | — | ||
| Q3 25 | $530.1M | — | ||
| Q2 25 | $500.1M | — | ||
| Q1 25 | $496.0M | — | ||
| Q4 24 | $486.0M | — | ||
| Q3 24 | $473.7M | — | ||
| Q2 24 | $457.6M | — |
| Q1 26 | $421.3M | — | ||
| Q4 25 | $429.4M | $49.4M | ||
| Q3 25 | $426.8M | $36.4M | ||
| Q2 25 | $437.8M | $44.5M | ||
| Q1 25 | $461.3M | $50.5M | ||
| Q4 24 | $476.0M | $55.1M | ||
| Q3 24 | $477.2M | $58.5M | ||
| Q2 24 | $497.8M | $60.4M |
| Q1 26 | $1.0B | — | ||
| Q4 25 | $990.8M | $59.0M | ||
| Q3 25 | $987.3M | $51.1M | ||
| Q2 25 | $966.3M | $60.7M | ||
| Q1 25 | $985.1M | $67.9M | ||
| Q4 24 | $992.6M | $90.6M | ||
| Q3 24 | $981.8M | $99.0M | ||
| Q2 24 | $983.2M | $107.8M |
| Q1 26 | — | — | ||
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.24× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 0.99× | — | ||
| Q2 24 | 0.92× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $56.4M | $18.4M | ||
| Q3 25 | $12.7M | $-8.7M | ||
| Q2 25 | $13.8M | $-7.5M | ||
| Q1 25 | $14.4M | $-7.5M | ||
| Q4 24 | $58.9M | $-24.0M | ||
| Q3 24 | $13.8M | $765.0K | ||
| Q2 24 | $16.7M | $-10.9M |
| Q1 26 | — | — | ||
| Q4 25 | $35.9M | — | ||
| Q3 25 | $7.6M | — | ||
| Q2 25 | $9.6M | — | ||
| Q1 25 | $9.7M | — | ||
| Q4 24 | $34.2M | — | ||
| Q3 24 | $6.7M | — | ||
| Q2 24 | $9.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | 116.0% | — | ||
| Q3 25 | 24.6% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 32.3% | — | ||
| Q4 24 | 116.9% | — | ||
| Q3 24 | 22.5% | — | ||
| Q2 24 | 34.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 66.3% | — | ||
| Q3 25 | 16.3% | — | ||
| Q2 25 | 14.5% | — | ||
| Q1 25 | 15.6% | — | ||
| Q4 24 | 84.1% | — | ||
| Q3 24 | 24.2% | — | ||
| Q2 24 | 26.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.91× | 1.50× | ||
| Q3 25 | 7.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.06× | — | ||
| Q4 24 | 32.14× | — | ||
| Q3 24 | 7.92× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHCT
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
